Comparative Pharmacology
Head-to-head clinical analysis: NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC versus NETROMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC versus NETROMYCIN.
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC vs NETROMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis. Polymyxin B is a polypeptide that disrupts bacterial cell membrane permeability by interacting with phospholipids. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan biosynthesis.
Netromycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in bacteria.
Apply thin layer to affected area 2-3 times daily. For ophthalmic use: 1-2 drops in affected eye every 4 hours, or 1/2 inch ribbon of ointment in conjunctival sac 2-3 times daily.
4-6 mg/kg IV once daily for serious infections; 1.5-2 mg/kg IV every 8 hours for gram-negative infections. Administered as intravenous infusion over 30-60 minutes.
None Documented
None Documented
Neomycin: 2-3 h (terminal), prolonged in renal impairment; polymyxin B: 6-7 h (terminal), extended in renal failure; bacitracin: 1.5 h (if absorbed), not clinically relevant due to minimal absorption.
Terminal elimination half-life is 2-3 hours in adults with normal renal function, but may extend to 24-48 hours in patients with impaired renal function.
Renal: ~90% of absorbed neomycin and polymyxin B; bacitracin zinc: minimal systemic absorption, excreted primarily in feces. For neomycin: ~99% fecal after oral; polymyxin B: ~60% renal, rest biliary; bacitracin: nearly 100% renal if absorbed.
Renal excretion of unchanged drug accounts for 80-90% of elimination via glomerular filtration; biliary/fecal elimination is minimal (<5%).
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic